Superworth

Genprex GNPX

Drug Manufacturers - General, Healthcare
$1.81
−8.59%
Market cap
$1.5M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for GNPX, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
n/an/an/an/an/an/an/an/an/an/an/an/a
R&D$4.6M+46%$3.7M+10%$3.3M−38%$1.7M−58%$2.8M−40%$2.8M−24%$2.5M−22%$2.5M+50%$2.2M−20%$2.2M−23%$2.7M+8%$2.7M+7%
SG&A$3.2M+5%$2.3M−29%$2.7M−31%$4.8M+20%$1.6M−51%$1.5M−34%$1.4M−47%$2.2M−55%$1.2M−26%$1.3M−12%$1.7M+22%$1.8M−18%
−$7.8M+26%−$6M−9%−$6M−35%−$6.5M−19%−$4.3M−45%−$4.3M−27%−$4M−34%−$4.7M−28%−$3.3M−23%−$3.5M−19%−$4.5M+13%−$4.5M−4%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
n/an/an/an/an/an/an/an/an/an/an/an/a
Net income−$7.7M+26%−$5.9M−9%−$6M−35%−$6.5M−19%−$4.3M−44%−$4.3M−27%−$4M−34%−$4.7M−28%−$3.8M−12%−$3.8M−13%−$4.5M+13%−$4.4M−5%
n/an/an/an/an/an/an/an/an/an/an/an/a
n/an/an/an/an/an/an/an/an/an/an/an/a

EPS, diluted: 5 periods, Q4 FY17 to Q4 FY21: quarter's net income to common over its shares, to the cent.

Diluted shares: 5 periods, Q4 FY17 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Genprex's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
GNPXGenprex$1.5Mn/mn/an/mn/mn/m
OXBROXBRIDGE RE HOLDINGS$7.7M47.5×9.6×2.8×+40%4.7%
EDUCEducational Development$8.7M5.4×11.3×0.4×−32%8.6%
GTIMGood Times Restaurants$13.6M6.1×13.6×0.1×−6%1.7%
Peer median$8.7M6.1×11.3×0.4×−6%4.7%

More on Genprex

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .